Search results
Results from the WOW.Com Content Network
Tilray Brands (NASDAQ: TLRY) shares still aren't delivering on what investors may have hoped for, falling by 25% during the past 12 months. Tilray isn't the same company it was a couple of years ...
Once a high-flying darling of the cannabis industry, Tilray has seen its stock price plummet a staggering 92% since its 2018 initial public offering (IPO), significantly underperforming the S&P ...
This worse-than-expected news is not necessarily a sign to buy the dip.
In the budding cannabis industry, there will be winners and losers. And for one-time heavyweight contender Tilray (NASDAQ:TLRY), a mixed earnings report has delivered another blow. But don't think ...
Shares of Tilray (TLRY) fell more than 17% on Tuesday after its post-IPO lockup period expired, allowing early investors in the Canadian marijuana company to cash out of their positions for the ...
As of 2 p.m., Aurora Cannabis (NASDAQ: ACB) shares were up 6%, Tilray ... Investors in marijuana stocks are reacting to what looks like good news, but I think they are marijuana ... Stock Advisor ...
Tilray Brands, Inc. is an American pharmaceutical, cannabis-lifestyle and consumer packaged goods company, incorporated in the United States, headquartered in New York City. [ 1 ] [ 2 ] Tilray also has operations in Canada, Australia, New Zealand, [ 3 ] [ 4 ] and Latin America, [ 5 ] with growing facilities in Germany and Portugal.
Overall, Tilray stock scores a Hold consensus rating based on 1 Buy, 8 Holds, and 1 Sell. The average analyst price target of $24.29 implies an upside potential of about 33% from current levels.